…
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. The company was founded in 1991 and is based in Minneapolis, Minnesota.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2014-06-30 | 2013-06-30 | 2012-06-30 | 2011-06-30 | 2010-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2014-06-30 | 2013-06-30 | 2012-06-30 | 2011-06-30 | 2010-06-30 |
| Income before tax | -7.62M | -4.28M | -4.64M | -3.73M | - |
| Net income | -7.61M | -4.29M | -4.70M | -3.73M | - |
| Selling general administrative | 8.15M | 10.23M | 9.97M | 7.90M | 10.44M |
| Gross profit | 5.90M | 8.35M | 8.38M | 6.54M | 8.97M |
| Ebit | -3.97M | -4.26M | -3.87M | -3.62M | - |
| Operating income | -3.97M | -4.26M | -3.87M | -3.62M | - |
| Other operating expenses | 0.10M | 0.10M | 0.09M | - | - |
| Interest expense | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Non recurring | 3.04M | 0.16M | 0.16M | - | - |
| Income tax expense | -0.02M | 0.01M | 0.06M | 0.01M | - |
| Total revenue | 14.01M | 16.48M | 17.03M | 12.57M | 14.77M |
| Total operating expenses | 17.98M | 20.74M | 20.89M | 16.19M | - |
| Cost of revenue | 8.12M | 8.13M | 8.64M | 6.03M | 5.80M |
| Total other income expense net | -3.65M | -0.02M | -0.77M | -0.10M | - |
| Net income from continuing ops | -7.61M | -4.29M | -4.70M | -3.73M | - |
| Net income applicable to common shares | -7.61M | -4.29M | -4.70M | -3.73M | - |
| Breakdown | 2014-06-30 | 2013-06-30 | 2012-06-30 | 2011-06-30 | 2010-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2014-06-30 | 2013-06-30 | 2012-06-30 | 2011-06-30 | 2010-06-30 |
| Total assets | 5.67M | 12.53M | 12.68M | 6.76M | 10.20M |
| Intangible assets | 1.37M | 1.59M | 2.26M | 0.10M | 0.12M |
| Other current assets | 0.06M | 0.13M | 0.29M | 0.25M | 0.14M |
| Total liab | 12.64M | 12.11M | 12.05M | 1.92M | 2.00M |
| Total stockholder equity | -6.98M | 0.42M | 0.63M | 4.85M | 8.21M |
| Deferred long term liab | 3.73M | 4.06M | 4.65M | - | - |
| Other current liab | 1.34M | 0.69M | 2.40M | 0.02M | 1.56M |
| Common stock | 0.21M | 0.21M | 0.15M | 0.14M | 0.14M |
| Retained earnings | -126.63M | -119.02M | -114.73M | -110.03M | - |
| Other liab | 3.77M | 4.14M | 4.76M | 0.16M | - |
| Good will | - | 3.04M | 3.12M | - | - |
| Other assets | 0.15M | 1.05M | 0.67M | 0.01M | 0.35M |
| Cash | 0.72M | 2.29M | 1.90M | 3.06M | 5.70M |
| Total current liabilities | 4.29M | 2.64M | 7.29M | 1.76M | 2.00M |
| Short term debt | 0.75M | 5.33M | - | - | - |
| Short long term debt | 0.75M | 5.33M | - | - | - |
| Property plant equipment | 0.47M | 0.73M | 0.86M | 0.86M | 1.01M |
| Total current assets | 3.68M | 6.12M | 5.77M | 5.79M | - |
| Net tangible assets | -8.35M | -4.20M | -4.75M | 4.74M | - |
| Net receivables | 1.50M | 2.13M | 2.13M | 1.36M | - |
| Long term debt | 4.59M | 5.33M | - | - | - |
| Inventory | 1.40M | 1.57M | 1.45M | 1.13M | 1.50M |
| Accounts payable | 0.89M | 0.63M | 3.38M | 0.74M | 0.43M |
| Breakdown | 2014-06-30 | 2013-06-30 | 2012-06-30 | 2011-06-30 | 2010-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2014-06-30 | 2013-06-30 | 2012-06-30 | 2011-06-30 | 2010-06-30 |
| Change to liabilities | 0.26M | 1.76M | 2.63M | 0.31M | - |
| Total cashflows from investing activities | -0.04M | -1.48M | -0.56M | -0.28M | - |
| Total cash from financing activities | - | 3.83M | 0.12M | 0.00M | 0.01M |
| Change to operating activities | 0.01M | -0.07M | 0.41M | -0.15M | - |
| Net income | -7.61M | -4.29M | -4.70M | -3.73M | - |
| Change in cash | -1.57M | 0.39M | -1.16M | -2.64M | - |
| Total cash from operating activities | -1.53M | -1.96M | -0.71M | -2.37M | - |
| Depreciation | 0.59M | 0.67M | 0.69M | 0.56M | - |
| Other cashflows from investing activities | -0.01M | -1.40M | -0.51M | - | - |
| Change to inventory | 0.27M | -0.63M | 0.13M | 0.24M | - |
| Change to account receivables | 0.62M | 0.02M | -0.74M | 0.07M | 0.08M |
| Sale purchase of stock | - | 3.83M | 0.12M | 0.00M | - |
| Change to netincome | 4.33M | 0.57M | 0.85M | 0.34M | - |
| Capital expenditures | 0.03M | 0.08M | 0.06M | 0.27M | 0.08M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ULGX Urologix Inc |
- -% |
0.00 | - | - | 0.00 | - | 0.40 | -9.52 |
| ABT Abbott Laboratories |
1.11 1.07% |
104.98 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
1.40 1.39% |
102.00 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
3.24 1.03% |
316.32 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
- -% |
48.34 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. The company was founded in 1991 and is based in Minneapolis, Minnesota.
| Name | Title | Year Born |
|---|---|---|
| Bryon Merade | Chairman & CEO | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.